OptiNose Inc (0OP F) stock market data APIs
€5.3515
0.22(4.3%)
as of February 28, 2025
OptiNose Inc Financial Data Overview
OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail. The company was founded in 2000 and is headquartered in Yardley, Pennsylvania.
Prev. Close
5.1341
Open
5.3515
High
5.3515
Low
5.1341
52 wk Range
0.15-25.23
Market Cap
4 303 K
Shares Outstanding
10 055 K
Revenue
75 672 K
Beta
-0.068
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get OptiNose Inc data using free add-ons & libraries
Get OptiNose Inc Fundamental Data
OptiNose Inc Fundamental data includes:
- Net Revenue: 75 672 K
- EBITDA: -18 856 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-03-05
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
OptiNose Inc News
New
Optinose Announces Preliminary Second Quarter 2023 XHANCE Net Revenue of $19.5 Million
Optinose, Inc. Second Quarter 2023 Conference Call and Webcast to be held August 10, 2023 at 8:00 a.m. Eastern Time Company plans to update full year 2023 XHANCE net revenue guidance on August 10 Y...
When Will OptiNose, Inc. (NASDAQ:OPTN) Breakeven?
With the business potentially at an important milestone, we thought we'd take a closer look at OptiNose, Inc.'s (NASDAQ:OPTN) future prospects. OptiNose, Inc., a specialty pharmaceutical company, focu...
Optinose Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Optinose, Inc. YARDLEY, Pa., June 16, 2023 (GLOBE NEWSWIRE) -- OptiNose, Inc. (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists...
OptiNose, Inc. (NASDAQ:OPTN) is definitely on the radar of institutional investors who own 39% of the company
Key Insights Given the large stake in the stock by institutions, OptiNose's stock price might be vulnerable to their trading decisions A total of 7 investors have a majority stake in the company with...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
